Natural killer cell killer immunoglobulin-like gene receptor polymorphisms in non-Hodgkin lymphoma: possible association with clinical course

Basit Öğe Kaydı
dc.authoridGürkan, Hakan/0000-0002-8967-6124
dc.authorwosidUyanik, Mehmet/AAD-7345-2020
dc.authorwosidGürkan, Hakan/AAF-2866-2020
dc.contributor.authorPamuk, Gulsum Emel
dc.contributor.authorTozkir, Hilmi
dc.contributor.authorUyanik, Mehmet Sevki
dc.contributor.authorGurkan, Hakan
dc.contributor.authorDuymaz, Julide
dc.contributor.authorPamuk, Omer Nuri
dc.date.accessioned2024-06-12T11:09:15Z
dc.date.available2024-06-12T11:09:15Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractNatural killer (NK) cell killer immunoglobulin-like receptors (KIRs) contribute to the pathogenesis of many diseases. We determined the association between polymorphisms of KIR and their ligands and susceptibility to non-Hodgkin lymphoma (NHL), clinical features and prognosis. We included 90 patients with NHL and 94 controls. In the NHL group, KIR2DS1, HLA-Bw4 (Thr80) and HLA-Bw4 (Thr80)+/Bw4 (Iso80)- ligands were significantly more frequent. Patients with early-stage NHL had more frequent KIR2DL5 and KIR2DL5B than patients with advanced-stage NHL. During a median follow-up of 27 months, 26 patients with NHL died. Poor prognostic factors in univariate analysis were KIR2DL5A, KIR2DS1 and KIR3DS1 genotypes. In multivariate Cox regression analysis, advanced age and early relapse were poor prognostic factors. KIR genes and ligands had no significant effect on survival. The activating KIR2DS1 gene might activate NK cells, contributing to the production of more lymphoma cells. In addition, KIR2DS1, KIR2DL5A and KIR3DS1 might also be associated with a poor prognosis in NHL.en_US
dc.description.sponsorshipTrakya University Scientific Research Fund (TUBAP), Edirne, Turkeyen_US
dc.description.sponsorshipThis study was funded by the Trakya University Scientific Research Fund (TUBAP), Edirne, Turkey.en_US
dc.identifier.doi10.3109/10428194.2015.1014361
dc.identifier.endpage2907en_US
dc.identifier.issn1042-8194
dc.identifier.issn1029-2403
dc.identifier.issue10en_US
dc.identifier.pmid25699652en_US
dc.identifier.scopus2-s2.0-84947609663en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage2902en_US
dc.identifier.urihttps://doi.org/10.3109/10428194.2015.1014361
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22747
dc.identifier.volume56en_US
dc.identifier.wosWOS:000365241700023en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofLeukemia & Lymphomaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNon-Hodgkin Lymphoma (NHL)en_US
dc.subjectNatural Killer (NK) Cellsen_US
dc.subjectKiller Immunoglobulin-Like Receptor (KIR)en_US
dc.subjectGenotypeen_US
dc.subjectPolymorphismen_US
dc.subjectNk Cellsen_US
dc.subjectKiren_US
dc.subjectExpressionen_US
dc.subjectHlaen_US
dc.titleNatural killer cell killer immunoglobulin-like gene receptor polymorphisms in non-Hodgkin lymphoma: possible association with clinical courseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu